Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1) / Fineberg, N. A.; Hollander, E.; Grant, J. E.; Chamberlain, S. R.; Drummond, L. M.; Pellegrini, L.; Laws, K. R.; Wellsted, D.; Reid, J.; Nezgovorova, V.; Baldwin, D. S.. - In: COMPREHENSIVE PSYCHIATRY. - ISSN 0010-440X. - ELETTRONICO. - 116:(2022), pp. 152323."-"-152323."-". [10.1016/j.comppsych.2022.152323]
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)
Pellegrini L.
;
2022-01-01
Abstract
Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., JAMA Psychiatry. 2022;79(3):193–200 (1)| File | Dimensione | Formato | |
|---|---|---|---|
|
1_s2.0_S0010440X22000293_main.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
342.43 kB
Formato
Adobe PDF
|
342.43 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
